IntelGenx to Participate in the 35th Annual Roth Conference
09 Mars 2023 - 4:35PM
IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (the
"Company" or "IntelGenx”), a leader in pharmaceutical films, will
be participating in the 35th Annual ROTH Conference, being held
March 12–14, 2023 at the Ritz-Carlton Hotel in Dana Point,
California.
IntelGenx’s President and CFO, Andre Godin, will
participate in a fireside chat hosted by Jonathan Aschoff, Ph.D.,
Managing Director, Senior Research Analyst at ROTH MKM, on Tuesday,
March 14, 2023, at 11:30 p.m. Pacific Time. Mr. Godin will also
participate in one-on-one meetings with investors during the
conference.
To arrange a one-on-one with IntelGenx, please
email oneononerequests@roth.com or contact your ROTH sales
representative to arrange.
About IntelGenxIntelGenx is a
leading drug delivery company focused on the development and
manufacturing of pharmaceutical films.
IntelGenx’s superior film technologies,
including VersaFilm®, DisinteQ™, VetaFilm™ and transdermal
VevaDerm™, allow for next generation pharmaceutical products that
address unmet medical needs. IntelGenx’s innovative product
pipeline offers significant benefits to patients and physicians for
many therapeutic conditions.
IntelGenx's highly skilled team provides
comprehensive pharmaceuticals services to pharmaceutical partners,
including R&D, analytical method development, clinical
monitoring, IP and regulatory services. IntelGenx's
state-of-the-art manufacturing facility offers full service by
providing lab-scale to pilot- and commercial-scale production. For
more information, visit www.intelgenx.com.
Forward-Looking Information and
Statements
This document may contain forward-looking
information about IntelGenx's operating results and business
prospects that involve substantial risks and uncertainties.
Statements that are not purely historical are forward-looking
statements within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended, and Section 27A of the Securities
Act of 1933, as amended. These statements include, but are not
limited to, statements about IntelGenx's plans, objectives,
expectations, strategies, intentions or other characterizations of
future events or circumstances and are generally identified by the
words "may," "expects," "anticipates," "intends," "plans,"
"believes," "seeks," "estimates," "could," "would," and similar
expressions. All forward looking statements are expressly qualified
in their entirety by this cautionary statement. Because these
forward-looking statements are subject to a number of risks and
uncertainties, IntelGenx's actual results could differ materially
from those expressed or implied by these forward-looking
statements. Factors that could cause or contribute to such
differences include, but are not limited to, those discussed under
the heading "Risk Factors" in IntelGenx's annual report on Form
10-K, filed with the United States Securities and Exchange
Commission and available at www.sec.gov, and also filed with
Canadian securities regulatory authorities at www.sedar.com.
IntelGenx assumes no obligation to update any such forward-looking
statements.
Source: IntelGenx Technologies Corp.
For IntelGenx:
Stephen KilmerInvestor Relations(647)
872-4849stephen@kilmerlucas.com
Or
Andre Godin, CPA, CAPresident and CFOIntelGenx
Corp.(514) 331-7440 ext 203andre@intelgenx.com
Intelgenx Technologies (TSX:IGX)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025
Intelgenx Technologies (TSX:IGX)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025